06 May 2013
The CAT at EMA recommended the classification of ImmuneSafe as an ATMP, precisely as a somatic cell therapy medicinal product following May’s meeting where this request was analysed. This classification together with the recently granted Orphan Designation allows submitting Protocol Assistance for the clinical trial targeting the demonstration of therapeutic efficacy of ImmuneSafe for the treatment of GvHD.
02 May 2013
Ref. 01/2013/PGMA: Procurement/Grant Management Assistant
Who we are
Cell2B is a biotechnology company dedicated to the development of advanced cellular therapies. Our goal is to deliver a new set of therapies to patients and caregivers to tackle immune, inflammatory, and oncological malignancies.
Cell therapies hold great promise to human health. Cells, in particular stem cells, have unique properties to renew damaged tissue or organ functions. Stem cells can be found in almost any tissue but in a reduced number. Cell2b is developing new proprietary techniques and protocols to increase their numbers and effectiveness in tissue and organ regeneration.
Procurement/Grant Management Assistant will be responsible for both procurement activities and grant management support. These include both international and national grants under the QREN framework.
Degree in life sciences/engineering or equivalent, preferably.
Minimum 2 years experience in Grant Management, particularly QREN grants.
Knowledge and experience with accounting systems, preferably PHC.
Excellent organizational and planning abilities.
Excellent communication skills.
Excellent English skills required (oral & written).
To apply for this position please email your CV, motivation letter and references for email@example.com. Please include the position reference in the subject.
29 April 2013
Cell2B won the 30 second and 2 minute pitch during the BIO convention in Chicago. The session was Son of a Pitch: Do you Have What it Takes to Win Over Investors in this Hands-On Workshop?
Daniela who is attending the event, won the opportunity to meet with Third Rock Venture’s partner Alexis Borisy. (more information here)
18 April 2013
Cell2B was granted today Orphan Designation for ImmuneSafe for the treatment of Graft versus Host Disease. This is an important development milestone for the company and reassures that development is in the right track.
18 April 2013
Cell2B is going to be present at BIO in Chicago. At the same time Cell2B is integrating the Portuguese Foreign Economy Agency’s Mission to Boston. See a report here.
18 April 2013
Cell2B was present at the Annual AAT meeting in Barcelone. This is the most important venue for Advanced Therapeutics. (More Information here)
03 January 2013
Following the Reuters report Cell2B was features at the New York Times in an article showcasing Bold Portuguese Start-ups that facing the economic crisis. Full article here.
23 December 2012
Cell2B was featured at Reuters as one of the companies that facing the current crisis in Portugal with Technology aiming at a global market. The story shows a path to economic growth based on new business and higher goals. Complete article here.